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The nucleus pulposus (NP)3 has a complex matrix that
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can within the network of collagen II. High concentration of
negatively charged sulfated glycosaminoglycans on aggrecan
allows the NP to attract sodium ions within the tissue, resulting
in physiologically elevated osmolarity compared with surrounding tissues. These cations also cause the NP tissue to
imbibe water, providing high osmotic swelling pressure responsible for the ability of discs to resist compressive loads in the
spine (1, 2). The increased matrix degradation by proteolysis,
changes in matrix composition, and inflammatory signaling
result in compromised mechanical function as well as
decreased osmolarity during intervertebral disc degeneration
(3–6). Moreover, the efflux and influx of water from discs
caused by diurnal loading of the spine lead to dynamic changes
of osmolarity in NP tissue. As a result, NP cells have evolved to
adapt to the changes in extracellular osmolarity.
Tonicity-responsive enhancer-binding protein (TonEBP/
nuclear factor of activated T-cells 5 (NFAT5)) is a Rel homology transcription factor, whose induction is coupled to
hyperosmolarity. TonEBP promotes cell survival by regulating the expression of osmoprotective genes in a variety of
tissues including NP (7, 8). Under osmotic stress, TonEBP
prevents excess influx of sodium by controlling the intracellular levels of nonionic osmolites such as taurine, sodium/
myoinositol, and betaine through regulation of their transporters and enzymes involved in their synthesis: taurine
transporter (TauT), betaine-GABA transporter (BGT-1),
sodium/myoinositol cotransporter (SMIT), and aldose reductase (AR) (8 –12). Additionally, heat shock protein 70
(HSP 70), a chaperone involved in cellular trafficking, protein
folding, and degradation of misfolded proteins, is regulated by
TonEBP under hyperosmotic condition (13).
In Madin-Darby canine kidney cells, TonEBP has been
shown to regulate cyclooxygenase-2 (COX-2), an enzyme necessary for prostaglandin (PG) synthesis (14). PGs are important
for regulating renal salt and water balance as well as inflammation (15). Other members of the NFAT family also control
COX-2 expression under various stimuli, including hyperosmolarity (16 –18). Whereas in renal cells COX-2 is linked to cell
survival and osmo-adaptation (19 –21), its regulation and function in the setting of hyperosmolarity remain largely unexplored in the disc. The objective of this study was to elucidate
how COX-2 expression is controlled in the hyperosmotic
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The nucleus pulposus (NP) of intervertebral discs experiences
dynamic changes in tissue osmolarity because of diurnal loading
of the spine. TonEBP/NFAT5 is a transcription factor that is
critical in osmoregulation as well as survival of NP cells in the
hyperosmotic milieu. The goal of this study was to investigate
whether cyclooxygenase-2 (COX-2) expression is osmoresponsive and dependent on TonEBP, and whether it serves an osmoprotective role. NP cells up-regulated COX-2 expression in
hyperosmotic media. The induction of COX-2 depended on elevation of intracellular calcium levels and p38 MAPK pathway,
but independent of calcineurin signaling as well as MEK/ERK
and JNK pathways. Under hyperosmotic conditions, both
COX-2 mRNA stability and its proximal promoter activity were
increased. The proximal COX-2 promoter (ⴚ1840/ⴙ123 bp)
contained predicted binding sites for TonEBP, AP-1, NF-B,
and C/EBP-␤. While COX-2 promoter activity was positively
regulated by both AP-1 and NF-B, AP-1 had no effect and
NF-B negatively regulated COX-2 protein levels under hyperosmotic conditions. On the other hand, TonEBP was necessary for
both COX-2 promoter activity and protein up-regulation in
response to hyperosmotic stimuli. Ex vivo disc organ culture studies using hypomorphic TonEBPⴙ/ⴚ mice confirmed that TonEBP
is required for hyperosmotic induction of COX-2. Importantly, the
inhibition of COX-2 activity under hyperosmotic conditions
resulted in decreased cell viability, suggesting that COX-2 plays a
cytoprotective and homeostatic role in NP cells for their adaptation
to dynamically loaded hyperosmotic niches.
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Figure 1. COX-2 is up-regulated in response to hyperosmolarity and high intracellular calcium in NP cells. A and B, qRT-PCR analysis demonstrates (A)
time- and (B) dose-dependent COX-2 mRNA increase under hyperosmotic conditions. C, COX-2 mRNA is induced by ionomycin/PMA (I ⫹ P) treatment. D and
E, Western blots of COX-2 after NaCl or I ⫹ P time course treatments show significant induction of COX-2 expression. F and G, densitometry analyses of Western
blots from D and E. H, immunofluorescence staining of COX-2 in NP cells confirms that its expression is increased with NaCl as well as I ⫹ P treatment. Scale bar:
50 m. All the quantitative data are represented as mean ⫾ S.D. from at least three independent experiments. *, p ⬍ 0.05.

milieu of NP cells as well as its functional implications. We
show that COX-2 expression is up-regulated under hyperosmotic conditions through intracellular calcium independent of
calcineurin signaling. In addition, we determine that this induction is through TonEBP-mediated increase in COX-2 proximal
promoter activity and its mRNA stability. Importantly, our
study demonstrates that COX-2 plays cytoprotective and
osmo-adaptive role in the hyperosmotic microenvironment of
the intervertebral disc.

Results
Hyperosmolarity and increased intracellular calcium
up-regulate COX-2 expression in NP cells
The effect of hyperosmolarity on COX-2 expression was
examined by culturing NP cells under hyperosmotic conditions
and measuring COX-2 mRNA and protein levels. COX-2

8970 J. Biol. Chem. (2018) 293(23) 8969 –8981

mRNA levels were significantly increased in response to NaCl
treatment at 4 h, and decreased to below the baseline level by
24 h (Fig. 1A). Treating NP cells with NaCl up to 170 mM
resulted in COX-2 mRNA up-regulation (Fig. 1B). All the
remaining experiments in this study were done with 110 mM
NaCl. Because extracellular hyperosmolarity leads to increased
[Ca2⫹]i in NP cells (22, 23), we examined the effect of increased
[Ca2⫹]i on COX-2 levels. Treatment with calcium ionophore,
ionomycin, with phorbol 12-myristate 13-acetate (PMA)
resulted in a significant induction of COX-2 mRNA at 4 and 8 h
(Fig. 1C). Although there was a decrease in the levels of COX-2
at 24 h post ionomycin/PMA treatment, the levels remained
higher than the baseline (Fig. 1C). Western blot analyses demonstrated induction of COX-2 protein levels in response to
hyperosmolarity and ionomycin/PMA treatment (Fig. 1, D–G).
COX-2 protein levels were significantly up-regulated at 4 and
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Figure 2. Hyperosmolarity-mediated induction of COX-2 is through intracellular calcium but independent of calcineurin signaling. A–C, hyperosmotic
induction of COX-2 mRNA (A), and protein (B and C) is suppressed by BAPTA, a calcium chelator, but is unaffected by FK-506/CsA (F/C), a calcineurin inhibitor.
D–F, induction of COX-2 mRNA (D) and protein (E and F) in response to ionomycin/PMA (I ⫹ P) treatment is completely abolished with BAPTA, but not with
FK/CsA treatment. All the quantitative data are represented as mean ⫾ S.D. from at least three independent experiments (three biological replicates). NS:
nonsignificant; *, p ⬍ 0.05.

8 h post hyperosmolarity and ionomycin treatments. Immunofluorescence staining supported the Western blot data showing
increased COX-2 levels with NaCl or ionomycin/PMA treatment (Fig. 1H).
Induction of COX-2 is independent of calcineurin pathway
Because calcineurin is an important mediator of calcium signaling, we investigated whether hyperosmolarity-induced
COX-2 up-regulation in NP cells involved calcineurin pathway. Cells were treated with NaCl with or without BAPTA, a
potent calcium chelator, or FK-506 and cyclosporin A (CsA),
calcineurin inhibitors. Reducing intracellular calcium levels
using BAPTA inhibited hyperosmotic induction of COX-2
mRNA and protein (Fig. 2, A–C). However, FK-506/CsA
treatment did not alter the NaCl-induced COX-2 levels,
indicating that COX-2 induction was independent of calcineurin signaling (Fig. 2, A–C). Similarly, ionomycin/PMAdependent induction of COX-2 mRNA and protein levels
were completely abolished by BAPTA, but not by FK-506/
CsA, confirming that calcineurin did not play a role in this
process (Fig. 2, D–F).

p38 MAPK pathway mediates hyperosmotic induction of
COX-2
Hyperosmolarity as well as calcium signaling is known to
activate MAPK signaling pathways (24 –28). Previous studies
also showed that MAPK pathways regulate COX-2 expression
in some cell types (29, 30). We therefore investigated if this
pathway contributed to regulation of COX-2 expression in NP
cells. We first determined the changes in activation status of
p38 in NP cells under hyperosmotic condition. Phospho-p38
levels were rapidly increased as early as 15 min and stayed significantly up-regulated until 1 h following NaCl treatment (Fig.
3, A and B). Although there was a trend of increasing phosphop38 at 5 min, 4 h, and 24 h, it did not reach statistical significance. We then treated NP cells with MAPK inhibitors including SB202190, p38 inhibitor; PD98059, MEK/ERK inhibitor;
and SP600125, JNK inhibitor, under hyperosmotic conditions
and measured COX-2 levels. Treating NP cells with p38 inhibitor
resulted in blockage of hyperosmotic induction of COX-2 mRNA
(Fig. 3C). However, inhibition of MEK/ERK or JNK pathways did
not affect COX-2 induction (Fig. 3D). Similarly, COX-2 protein
up-regulation in response to NaCl treatment was abolished with
J. Biol. Chem. (2018) 293(23) 8969 –8981
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Figure 3. Hyperosmotic induction of COX-2 is mediated by p38, but not by ERK or JNK. A and B, phospho-p38 (p-p38) levels significantly increase in
response to hyperosmolarity. C and D, hyperosmotic increase of COX-2 mRNA is completely suppressed by p38 inhibitor, SB202190, but unaffected by JNK
inhibitor, SP600125, and MEK/ERK inhibitor, PD98059. E, Western blot images showing that p38 inhibition prevents COX-2 induction in response to hyperosmolarity. F, Western blot images showing that ionomycin/PMA (I ⫹ P)-mediated COX-2 induction is not affected by p38 inhibition. G, densitometry analyses of
Western blots shown in E and F. All the quantitative data are represented as mean ⫾ S.D. from at least three independent experiments (three biological
replicates). NS: nonsignificant; *, p ⬍ 0.05. PD: PD98059 (MEK/ERK inhibitor); SB90: SB202190 (p38 inhibitor); SP: SP600125 (JNK inhibitor).

p38 inhibition, indicating that p38 MAPK is involved in hyperosmotic induction of COX-2. However, when NP cells were treated
with ionomycin/PMA, p38 inhibition had no effect on COX-2 upregulation (Fig. 3, E–G), suggesting that p38 MAPK is dispensable
to ionomycin-induced COX-2 expression.
Hyperosmolarity increases COX-2 transcription as well as its
mRNA stability
To further elucidate the mechanism of COX-2 induction by
hyperosmolarity, we first investigated if hyperosmolarity affects
COX-2 mRNA stability. Actinomycin D chase study showed that
in NP cells, the half-life of COX-2 mRNA under isoosmotic condition was ⬃2 h, whereas under hyperosmotic condition it was
longer than 6 h (Fig. 4A), suggesting that increased COX-2 expression was in part due to elevated mRNA stability.
Because MAPK pathways are involved in activation of various transcription factors, we investigated if hyperosmotic
induction of COX-2 was also transcriptionally regulated. Lucif-
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erase reporter assays were performed using COX-2 promoter
fragment (⫺1840/⫹123 bp) that has shown transcriptional regulatory activity in other cell types (31). Genomatix MatInspector software was used to scan potential TonE- and other relevant transcription factor– binding sites within the COX-2
promoter (Fig. 4B). Putative binding sites and consensus
sequence for each transcription factor with four core consensus
bp in capital letters are listed in the table (Fig. 4C). Matrix similarity score based on the most conserved nucleotide at each
position of the matrix is also shown. Four TonE sites as well as
binding sites for AP-1, C/EBP-␤, and NF-B were identified.
We assessed the sensitivity of the promoter to hyperosmotic
stimuli; the promoter activity was significantly increased at 4 h,
and then declined at 24 h (Fig. 4D). COX-2 promoter activity
also showed dose-dependent induction in response to hyperosmolarity (Fig. 4E). In addition, hyperosmotic induction of
COX-2 promoter activity was reduced to basal level when the
cells were treated with BAPTA, supporting our earlier data on
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Figure 4. Both increased mRNA stability and proximal promoter activity account for COX-2 up-regulation in response to hyperosmolarity. A, actinomycin D chase study demonstrates that estimated half-life of COX-2 mRNA is increased by hyperosmolarity, representing increased mRNA stability (n ⫽ 5). B,
a schematic showing TonEBP, AP-1, NF-B, and C/EBP-␤– binding sites on ⬃1.8 kb COX-2 proximal promoter region. C, list of putative binding sites and
consensus sequence for each transcription factor. Four bp core consensus sequence used for query was marked as capital letters. Matrix similarity score based
on the most conserved nucleotide at each position of the matrix is also shown. D and E, COX-2 promoter activity shows (D) time- and (E) dose-dependent
increase under hyperosmotic conditions. F, hyperosmolarity-dependent increase of COX-2 promoter activity is inhibited with a calcium chelator, BAPTA. G and
H, up-regulation of COX-2 promoter activity under hyperosmotic condition was inhibited by p38 inhibitor (SB90) and MEK/ERK inhibitor (PD). All the quantitative data are represented as mean ⫾ S.D. from at least three independent experiments (three biological replicates). Promoter activity experiments were done
with three technical replicates per independent experiment. NS: nonsignificant; *, p ⬍ 0.05. SB90: SB202190 (p38 inhibitor); PD: PD98059 (MEK/ERK inhibitor).

calcium-dependent induction of COX-2 mRNA and protein
levels under hyperosmotic conditions (Fig. 4F). Similarly, when
the cells were treated with p38 inhibitor under hyperosmotic
condition, COX-2 promoter activity was decreased to that of
baseline (Fig. 4G). Interestingly, inhibition of p38 under isoosmotic condition resulted in increased COX-2 promoter activity
(Fig. 4G). Furthermore, although COX-2 mRNA levels were not
affected, its promoter activity was significantly reduced by

MEK/ERK inhibitor (Fig. 4H). These results indicated that
hyperosmotic induction of COX-2 was because of increased
mRNA stability as well as transcription.
AP-1, C/EBP-␤, and NF-B do not contribute to hyperosmotic
induction of COX-2 expression
Because we identified several potential transcription factor–
binding sites in the ⬃1.8 kb proximal promoter region of
J. Biol. Chem. (2018) 293(23) 8969 –8981
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Figure 5. AP-1, NF-B, and C/EBP-␤ are not involved in hyperosmotic induction of COX-2. A, luciferase assay using AP-1 reporter shows that AP-1 activity
is up-regulated by hyperosmolarity. B, COX-2 promoter activity under hyperosmotic condition is significantly decreased by DN–AP-1. C and D, AP-1 inhibition
by a specific inhibitor, SR11302, does not block hyperosmotic induction of COX-2. E, COX-2 promoter activity is decreased by DN–NF-B, but unaltered by
DN–C/EBP-␤. F, unlike the promoter activities, COX-2 mRNA levels are further up-regulated by NF-B inhibitor, SM7368, under hyperosmotic condition. G–I,
NF-B inhibition resulted in further up-regulation of COX-2 protein levels under hyperosmotic condition, but had no effect when the cells were treated with
ionomycin/PMA. All the quantitative data are represented as mean ⫾ S.D. from at least three independent experiments (three biological replicates). Promoter
activity experiments were done with three technical replicates per independent experiment. NS: nonsignificant; *, p ⬍ 0.05. SR: SR11302 (AP-1 inhibitor); SM:
SM7368 (NF-B inhibitor); I ⫹ P: ionomycin/PMA.

COX-2, we determined whether these transcription factors
were responsible for modulating COX-2 transcription. AP-1
has been shown to regulate COX-2 expression (32, 33), and we
and others have shown that AP-1 and TonEBP coregulate
expression of certain target genes (28, 34). Therefore, we first
investigated if AP-1 activity was modified under hyperosmotic
conditions. AP-1–responsive reporter activity showed significant increase in response to NaCl treatment (Fig. 5A). In addition, dominant negative (DN)–AP-1 (A-Fos) significantly suppressed COX-2 promoter activity under both isoosmotic and
hyperosmotic conditions (Fig. 5B). Surprisingly however,
COX-2 protein levels remained elevated when NP cells were
treated with AP-1–specific inhibitor, SR11302, under hyperosmotic condition (Fig. 5, C and D). Inhibition of AP-1 under
isoosmotic condition also resulted in elevated COX-2 levels,
suggesting that AP-1 is a negative regulator of COX-2 in NP
cells.
NF-B has also been shown to control COX-2 expression
in other types of cells under hyperosmotic conditions (35,

8974 J. Biol. Chem. (2018) 293(23) 8969 –8981

36). For example, renal medullary interstitial cells up-regulate COX-2 in response to hyperosmotic stimuli through coactivation of NF-B and C/EBP-␤ (36). We investigated
whether such regulatory mechanism exists in NP cells.
Transfecting cells with DN–NF-B resulted in slight but
statistically significant decrease in COX-2 promoter activity under both isoosmotic and hyperosmotic conditions,
whereas DN–C/EBP-␤ did not affect COX-2 promoter activity (Fig. 5E). However, in contrast to the decreased promoter
activity, COX-2 mRNA as well as protein levels were further
up-regulated by NF-B inhibitor, SM7368 (Fig. 5, F, G, and
I), suggesting that NF-B was not responsible for hyperosmotic induction of COX-2 but rather served as a negative
regulator in NP cells. Interestingly, when cells were treated
with ionomycin/PMA, NF-B inhibition had no significant
effect on COX-2 expression (Fig. 5, H and I), suggesting
that NF-B is not involved in ionomycin-induced COX-2
expression.
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TonEBP regulates COX-2 expression in response to
hyperosmolarity
Because TonEBP/NFAT5 is an important mediator of
osmotic response and known to be activated in a calcium-dependent but calcineurin-independent manner (22, 23), and
because COX-2 proximal promoter had four predicted
TonEBP-binding sites, we investigated whether hyperosmotic
induction of COX-2 in NP cells was through TonEBP. To assess
the role of TonEBP in regulation of COX-2 promoter, we
performed gain- and loss-of-function experiments. TonEBP
overexpression increased, whereas DN–TonEBP significantly
decreased COX-2 promoter activity (Fig. 6, A and B). The
involvement of TonEBP in COX-2 regulation was further tested
through stably silencing TonEBP by transducing NP cells
with lentivirus expressing either control or TonEBP-targeting
shRNA. In the absence of TonEBP, hyperosmotic up-regulation
of COX-2 mRNA was inhibited (Fig. 6C). Under both isoosmotic and hyperosmotic conditions, COX-2 protein levels
were significantly decreased by TonEBP silencing (Fig. 6, D and
E), indicating that hyperosmotic induction of COX-2 was
TonEBP-dependent. To confirm these findings, we analyzed
COX-2 expression in WT and TonEBP null mouse embryonic
fibroblasts (MEFs) in response to hyperosmolarity and ionomy-

cin/PMA treatments. Under both conditions, WT MEFs increased COX-2 expression. In contrast, TonEBP null MEFs
failed to up-regulate COX-2 levels (Fig. 7, A and B). We also
performed an ex vivo organ culture study using intervertebral
discs from WT (TonEBP⫹/⫹) and haploinsufficient TonEBP
heterozygous mice (TonEBP⫹/⫺) (Fig. 7C). Culturing under
hyperosmotic condition resulted in COX-2 mRNA up-regulation in the WT discs, but not in the TonEBP⫹/⫺ discs (Fig. 7D),
further supporting the role of TonEBP in regulating COX-2
expression under hyperosmotic condition.
COX-2 activity promotes NP cell survival
Because many of the TonEBP targets induced under osmotic
stress promote cell survival, we investigated the functional
importance of COX-2 under hyperosmotic condition. NP cell
viability was measured following culture in isoosmotic or
hyperosmotic media, with or without celecoxib, a COX-2
inhibitor. Celecoxib treatment reduced cell viability under
isoosmotic condition (Fig. 7E). Moreover, under hyperosmotic
condition, celecoxib treatment resulted in even further cell death,
suggesting that COX-2 plays an important cytoprotective function
in NP cells (Fig. 7E). To further delineate if COX-2–mediated cell
survival was through inhibition of caspase activity, we treated cells
J. Biol. Chem. (2018) 293(23) 8969 –8981
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with different caspase inhibitors in the presence of celecoxib.
Interestingly, treatment with AZ10417808 (caspase-3 inhibitor),
Z-IE(OMe)TD(OMe)–FMK (caspase-8 inhibitor), or Boc-DFMK (pan caspase inhibitor) failed to block cell death caused by
celecoxib (Fig. 7E), suggesting that COX-2 did not mediate its
cytoprotective effects through inhibition of caspase activity.

Discussion
In this study, we elucidated the mechanism of COX-2
expression in NP cells in response to hyperosmotic stress. We
demonstrated that COX-2 mRNA and protein were up-regulated by hyperosmolarity through calcium signaling activating
p38 and TonEBP. Our data suggested that both COX-2 tran-
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scription and COX-2 mRNA stability were increased under
hyperosmotic condition. Interestingly, both processes were dependent on TonEBP as shown by gain- and loss-of-function
studies and TonEBP⫹/⫺ mouse disc ex vivo organ culture study.
The functional analysis showed that COX-2 activity was crucial
for NP cell survival not only under isoosmotic condition, but
more so under hyperosmotic stress. Taken together, our study
showed that COX-2 is a TonEBP target in NP cells, and that it
plays a cytoprotective role during acute osmotic challenge.
Several studies have shown that different stimuli, including
high glucose levels, dehydration-caused hyperosmolarity, and
inflammatory stimuli, can induce COX-2 expression (14, 16, 17,
35, 37). Our results showed that COX-2 was induced in NP cells
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PKA and ROS have been linked to TonEBP activation (43, 44).
We therefore hypothesized that TonEBP may be involved in
COX-2 regulation. There have been a few studies demonstrating association between TonEBP and COX-2 expression in different cell types (14, 45). However, none of the previous studies
have investigated the role of TonEBP in controlling COX-2
proximal promoter activity. Our analysis predicted four TonE
sites within the proximal 1.8 kb promoter region of COX-2.
TonEBP gain- and loss-of-function experiments showed that
COX-2 promoter activity was responsive to TonEBP. In contrast to AP-1 and NF-B, stable silencing of TonEBP resulted in
inhibition of hyperosmotic up-regulation of COX-2 in NP cells.
Further support for TonEBP contribution to COX-2 regulation
was evident from analyses of TonEBP null MEFs. COX-2 protein expression was responsive to neither hyperosmolarity nor
high intracellular calcium in TonEBP null MEFs. Importantly,
ex vivo disc organ culture studies using haploinsufficient
TonEBP⫹/⫺ mice firmly supported in vitro studies. In the intervertebral discs of TonEBP⫹/⫺ mice, COX-2 gene expression
was not induced by hyperosmolarity, confirming that TonEBP
is necessary for COX-2 expression under hyperosmotic stress
in NP cells. Although TonEBP has been associated with both
AP-1 and NF-B in regulating certain targets in NP cells under
certain conditions (28, 45– 47), this was not the case in controlling COX-2 expression, implying its target-specificity. Furthermore, complete inhibition of COX-2 up-regulation in the
absence of TonEBP indicated that TonEBP not only transcriptionally regulates COX-2, but also indirectly stabilizes
COX-2 mRNA under hyperosmotic condition. Interestingly,
the magnitude of increase in COX-2 promoter activity in
response to hyperosmolarity or TonEBP overexpression is
subdued compared with the increase in half-life of COX-2
mRNA. This suggests that, unlike in other cell types, the
main mode of TonEBP regulation of COX-2 in NP may be
through mRNA stabilization.
The function of COX-2 as an osmoprotective factor has been
shown in leukemia (48) and renal cells (19 –21). NP cells, similar to renal cells, require tight osmoregulation to protect cells
from deleterious effects of dynamic changes in osmolarity and
mechanical loading. Therefore, we hypothesized that TonEBPmediated dynamic COX-2 expression serves a cytoprotective
and homeostatic role rather than an inflammatory function in
NP cells. Cell viability assay following COX-2 activity inhibition
clearly demonstrated that COX-2 activity contributed to NP
cell survival regardless of extracellular osmolarity. It is noteworthy that inhibition of caspases did not rescue compromised
cell viability caused by COX-2 inhibition, indicating that the
observed cell death was caspase-independent. This was different from what has been seen in leukemia cells, where COX-2
promotes cell survival by activating anti-apoptotic proteins
Bcl-2 and Bcl-xL, and preventing caspase-3, poly [ADP-ribose]
polymerase (PARP), and lamin B cleavage through its target,
PGE2 (48).
Taken together, our study demonstrated that calciumMAPK-TonEBP axis plays a critical role in controlling COX-2
expression in NP cells under hyperosmotic condition, and that
COX-2 serves a prosurvival function. It should be noted that
the function of COX-2 is context-dependent as has been demJ. Biol. Chem. (2018) 293(23) 8969 –8981
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in response to osmotic challenge as well as ionomycin/PMA
treatment. Both stimuli resulted in the highest induction of
COX-2 by 4 h and significant decrease at 24 h following hyperosmotic stimulus. This suggested that COX-2 induction is a
relatively early response and that the temporal regulation of its
expression is important. In various cell types, COX-2 expression is regulated by intracellular calcium through several pathways including calcineurin-NFAT as well as reactive oxygen
species (ROS) and cAMP activation (18, 39 – 41). The data from
our studies using calcium chelator BAPTA confirmed that
hyperosmolarity- and ionomycin-mediated COX-2 expression
is through changes in intracellular calcium levels. Interestingly,
when NP cells were treated with calcineurin inhibitors FK-506/
CsA, COX-2 induction by hyperosmolarity or ionomycin
remained unaltered, indicating that COX-2 up-regulation in
response to hyperosmolarity or ionomycin is independent of
calcineurin-NFAT pathway.
In renal medullary interstitial cells, MAPK pathway, known
to be downstream of calcium signaling, modulates COX-2
expression under hyperosmotic condition (29, 30). Our data
clearly showed that MAPK, specifically p38, was involved in
hyperosmotic induction of COX-2 in NP cells. On the other
hand, COX-2 induction by ionomycin treatment was not
responsive to p38 inhibition, indicating that in presence of
excessively high levels of intracellular calcium, p38 activity is
redundant in promoting COX-2.
MAPK pathways have been shown to regulate multiple transcription factors, including TonEBP, NFATs, AP-1, and NF-B,
that have been implicated in COX-2 regulation (14, 16, 17, 32,
33, 35, 36). Our analysis showed that COX-2 promoter has multiple predicted binding sites for TonEBP as well as other transcription factors. Induction of COX-2 promoter activity under
hyperosmotic condition that mirrors the mRNA expression
profile showed that the increase in COX-2 expression was in
part because of increased transcription. Moreover, COX-2 promoter sensitivity to BAPTA treatment confirmed that this transcriptional induction was calcium-dependent. Importantly,
actinomycin D chase experiment clearly demonstrated that
COX-2 mRNA was significantly stabilized under hyperosmotic
condition, indicating that up-regulation of COX-2 is because of
combinatorial effect of transcriptional regulation and increased
mRNA stability.
Both AP-1 and NF-B have been implicated in COX-2 regulation in a cell type– and context-dependent manner (35, 36).
Our promoter studies revealed that although both transcription factors modulated COX-2 promoter activity, under hyperosmotic conditions, AP-1 did not regulate COX-2 protein
levels, whereas, NF-B evidenced a negative relationship to
COX-2 levels. This discordance suggests that AP-1 and NF-B
do not control COX-2 transcription through its proximal promoter in response to hyperosmotic stimuli, and that they are
not the primary inducers of hyperosmolarity-mediated COX-2
expression in NP cells. In addition, despite the presence of
C/EBP-␤– binding sites, these sites did not contribute to hyperosmotic regulation of COX-2 promoter activity.
Our earlier work has shown that hyperosmolarity-dependent
TonEBP activation in NP cells was through increased [Ca2⫹]i,
yet did not involve calcineurin pathway (22, 23). Likewise, both
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onstrated in the cases of fracture healing and inflammatory diseases of bone and other tissues (49 –51). Inhibition of COX-2
has been shown to be beneficial in treating inflammation of
herniated discs as well (52). Our study reveals a novel function
of COX-2 in maintaining intervertebral disc health, and has an
important clinical implication as chronic use of NSAIDs for
back pain or other musculoskeletal diseases may alleviate pain
and reduce inflammation in pathological discs but can also
inhibit COX-2 in other healthy discs, adversely affecting the NP
health. Therefore, it is crucial to understand underlying mechanisms that distinguish physiological and homeostatic versus
pathological roles of COX-2 in the disc. Our study provides a
better understanding on the regulatory mechanism of a key
cellular pathway necessary for NP cell survival and function.

Reagents and plasmids
Plasmids were kindly provided by Drs. Ben C. Ko, University
of Hong Kong (FLAG–DN–TonEBP, FLAG–TonEBP, FLAG–
CMV2 (53); DN–TonEBP contains amino acids 157 through
581 of human TonEBP (from clone KIAA0827)); Charles Vinson, NIH (DN–AP-1); Silvio Gutkind, NIH (AP-1 reporter);
Dan Dixon, University of South Carolina (1.8 kb human COX-2
promoter luciferase reporter construct (31)). psPAX2 (no.
12260) and pMD2.G (no. 12259) developed by Dr. Didier
Trono, and pCMV–FLAG–LIP (DN–C/EBP-␤; no. 15737) by
Dr. Joan Massague were obtained from Addgene. Lentiviral
shTonEBP (TRCN0000020019) and control shRNA plasmids
were purchased from Sigma. TonEBP/NFAT5 WT and null
MEFs (from Dr. Steffan N. Ho) (42) were provided by Dr. Feng
Chen, Washington University, St. Louis. TonEBP⫹/⫹ and haploinsufficient TonEBP⫹/⫺ developed by Dr. Steffan Ho (42)
were a kind gift from H. Moo Kwon, Ulsan National Institute of
Science and Technology.
Cell culture and treatments
Rat NP cells were isolated using a method previously
reported by Risbud et al. (38) and approved by Jefferson’s Institutional Animal Care and Use Committee. Cells were maintained in DMEM with 10% FBS supplemented with antibiotics
until confluent. For hyperosmolarity treatment, 110 or 170 mM
NaCl was added to the culture media for NP cells, resulting in
550 and 670 mOsM kg⫺1 media, respectively, and 85 mM NaCl
was added to the culture media for TonEBP WT and null MEFs,
resulting in 500 mOsM kg⫺1 media. In some experiments, cells
were treated with 1 M ionomycin (Sigma) and 100 ng/ml PMA
(Sigma) with or without pretreatment with either 10 M
BAPTA/AM (EMD Millipore) or FK-506 (10 ng/ml)/CsA (1
g/ml) (EMD Millipore) for 1.5 h. In some experiments, cells
were pretreated with 10 M SB202190 (Tocris Bioscience), 10
M PD98059 (Tocris), 10 M SP600125 (Sigma), 10 M SM7368
(Calbiochem), 10 M SR11302 (Tocris), 30 M AZ10417808
(Tocris), 20 M Z-IE(OMe)TD(OMe)-FMK (Calbiochem), 100
M Boc-D-FMK (Calbiochem), or 40 M celecoxib (Sigma) for
1–1.5 h prior to NaCl or iononomycin/PMA treatment.
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Total RNA was extracted from NP cells using RNeasy Mini
columns (Qiagen). The purified, DNA-free RNA was converted
to cDNA using RNA to cDNA EcoDryTM Premix (Clontech).
Template cDNA and gene-specific primers were added to
SYBR Green Master Mix (Applied Biosystems) and mRNA
expression was quantified using the Step One Plus Real-Time
PCR System (Applied Biosystems). ␤-actin was used to normalize gene expression. All the primers used were synthesized by
Integrated DNA Technologies, Inc. (Coralville, IA).
Bioinformatic analysis of promoter
Human COX-2 proximal promoter sequence was downloaded from the University of California, Santa Cruz Genome
Table Browser. MatInspector (Genomatix) was used to identify
predicted binding sites for TonEBP as well as AP-1, NF-B, and
C/EBP-␤ with a Matrix Similarity Score cutoff of 0.8.
Transfections and dual luciferase assay
Cells were plated on 48-well plates (2 ⫻ 104 cells/well) 1 day
before transfection. Cells were transfected with 250 ng of
COX-2 reporter plasmid and 250 ng of pRL-TK plasmid, or 150
ng of COX-2 reporter plasmid, 150 ng of various dominantnegative or overexpression plasmids, with or without appropriate backbone vector, and 200 ng of pRL-TK plasmid. For each
transfection, plasmids were premixed with the transfection reagent Lipofectamine 2000 (Invitrogen). The treatments were
done so that the cells were lysed 48 h after the transfection.
Dual-LuciferaseTM reporter assay system (Promega) was used
for sequential measurements of firefly and Renilla luciferase
activities using TECAN Infinite200 Pro microplate reader
(TECAN). At least three independent transfections were performed and all analyses were carried out in triplicate.
Protein extraction and Western blotting
Following treatment, cells were immediately placed on ice
and washed with ice-cold PBS. All the wash buffers and the final
cell lysis/resuspension buffers included 1⫻ protease inhibitor
mixture (Roche), NaF (5 mM), and Na3VO4 (200 M). Proteins
were resolved on 10% SDS-polyacrylamide gels and transferred
by electroblotting to PVDF membranes (Bio-Rad). The membranes were blocked with 5% nonfat dry milk in TBS with
Tween 20 and incubated overnight at 4 °C in 5% nonfat dry milk
in TBS with Tween 20 with the antibodies against COX-2
(1:1000; no. 12282, rabbit, Cell Signaling Technology), phospho-p38 (1:1000; no. 8690, rabbit, Cell Signaling Technology),
NFAT5 (1:1000; no. NB120 –3446, rabbit, Novus), or GAPDH
(1:3000; NB300 –221, mouse, Novus), and then appropriate
secondary antibodies for 1 h at room temperature. Immunolabeling was detected using the ECL reagent (Amersham
Biosciences).
Immunofluorescence microscopy
NP cells were plated on glass coverslips. Following treatment
cells were fixed and permeabilized with cold methanol at
⫺20 °C for 15 min, blocked with 5% normal goat serum in PBS
with 0.3% Triton X-100 for 1 h at room temperature. Cells were
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incubated with anti–COX-2 antibody (1:800; no. 12282, rabbit,
Cell Signaling Technology) at 4 °C overnight, then incubated
with Alexa Fluor 594 secondary antibody (1:800; Jackson
ImmunoResearch Laboratories) at room temperature for 1 h.
Cells were washed and were mounted with ProLongTM Gold
Antifade Mountant with DAPI (Thermo Fisher). All mounted
slides were visualized using a Zeiss Axio Imager A2 (Carl Zeiss).
Cell viability assay

Lentiviral particle production and viral transduction
HEK293T cells were plated in 10-cm plates (5 ⫻ 106 cells/
plate) in DMEM with 10% heat-inactivated FBS 1 day before
transfection. Cells were transfected with 9 g of sh-Ctr or shTonEBP plasmids along with 6 g psPAX2 and 3 g pMD2.G
using Lipofectamine 2000 (Invitrogen). After 6 h, transfection
media were replaced with fresh DMEM with 10% FBS. Lentiviral media were harvested at 48 to 60 h post transfection, and
virus was precipitated using 7% PEG 6000 solution. NP cells
were transduced with fresh media containing viral particles
along with 8 g/ml Polybrene. Cells were harvested for protein
extraction 4 –5 days after transduction to ensure maximum
knockdown efficiency.
Ex vivo disc organ culture
TonEBP⫹/⫹ and haploinsufficient TonEBP⫹/⫺ mice on
C57BL/6 background were socially housed under barrier conditions using aseptic techniques. Mice were provided with Lab
Diet 5010 Laboratory Autoclavable Rodent Diet ad libitum.
Both male and female mice at 4 months were sacrificed according to the guidelines by the Thomas Jefferson University’s Institutional Animal Care and Use Committee. Whole spines were
dissected from mice en bloc and muscle, tendon, and ligaments
were carefully removed. Individual motion segments, including
vertebral bone and the intervertebral disc were isolated and
allowed to equilibrate overnight in DMEM with 10% FBS. For
each experimental group, lumbar and caudal motion segments
from a single mouse were pooled together. The next day, fresh
media with or without 110 mM NaCl were added for 8 h. After
treatment, vertebrae and bony endplates were removed from
the intervertebral disc using a dissecting microscope (Zeiss
Stemi 305), and discs were snap frozen in liquid nitrogen and
pulverized using a BioSpec BioPulverizer before RNA isolation.
Statistical analysis
All measurements were performed in at least three independent experiments. No data were excluded. Data are presented
as the mean ⫾ S.D. Differences between groups were assessed
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